Upexi Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Allan Marshall

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	66.1%
Dienstverband CEO	5.5yrs
Eigendom CEO	14.1%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Allan Marshall's beloning veranderd ten opzichte van Upexi's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	n/a	n/a	-US$20m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	US$1m	US$840k	-US$15m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	n/a	n/a	-US$1m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	US$5m	US$840k	-US$6m
Mar 31 2022	n/a	n/a	-US$923k
Dec 31 2021	n/a	n/a	US$244k
Sep 30 2021	n/a	n/a	US$3m
Jun 30 2021	US$1m	US$285k	US$3m
Mar 31 2021	n/a	n/a	-US$470k
Dec 31 2020	n/a	n/a	-US$3m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	US$2m	US$300k	-US$5m

Compensatie versus markt: De totale vergoeding ($USD 1.27M ) Allan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.65K ).

Compensatie versus inkomsten: De vergoeding van Allan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Allan Marshall (57 yo)

5.5yrs

Tenure

US$1,271,068

Compensatie

Mr. Allan J. Marshall is Chief Executive Officer at Upexi, Inc. (formerly known as Grove, Inc.) since May 2019 and has been its Director since May 17, 2019. Mr. Marshall joined the Company as Chief Executi...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Allan Marshall	CEO, President & Chairman of the Board	5.5yrs	US$1.27m	14.07% $ 1.2m
Andrew Norstrud	CFO & Director	4.8yrs	US$430.00k	1.46% $ 122.8k
Eugene Salkind	Independent Director	3.8yrs	US$148.50k	11.72% $ 983.9k
Thomas Williams	Independent Director	3.8yrs	US$148.50k	geen gegevens
Lawrence Dugan	Independent Director	3.8yrs	US$150.50k	0.13% $ 11.2k

3.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van UPXI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Upexi Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Upexi, Inc., Annual General Meeting, Jun 10, 2024

Insufficient new directors

Upexi, Inc., Annual General Meeting, Jun 26, 2023

CEO, President & Chairman of the Board recently bought US$73k worth of stock

High number of new and inexperienced directors

Recent updates

Upexi, Inc. to Report Fiscal Year 2024 Results on Nov 01, 2024

Nasdaq Grants Additional 180 Days to Upexi to Regain Compliance with Minimum Bid Price Requirement

Upexi, Inc. announced delayed annual 10-K filing

Insufficient new directors

David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

E-Core Holdings, LLC acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024

MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc., Annual General Meeting, Jun 10, 2024

New major risk - Market cap size

Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 17%

This Analyst Just Downgraded Their Upexi, Inc. (NASDAQ:UPXI) EPS Forecasts

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog Supplements

Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.

Upexi, Inc. (NASDAQ:UPXI) Doing What It Can To Lift Shares

Upexi, Inc., Annual General Meeting, Jun 26, 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Upexi, Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)

CEO, President & Chairman of the Board recently bought US$73k worth of stock

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.

Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.

Upexi, Inc. Files Patent for its Single Click-to-optin Technology

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)

Upexi, Inc. Appoints Anthony Bazan as Chief Operating Officer

Investor sentiment deteriorated over the past week

Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.

Investor sentiment improved over the past week

Grove CEO provides company update on sales and beyond

Investor sentiment improved over the past week

Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.

Grove, Inc., Annual General Meeting, May 24, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)

Investor sentiment improved over the past week

Why Grove's (NASDAQ:GRVI) Earnings Are Weaker Than They Seem

Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)

Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.

Grove: An Underrated CBD Player

Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation.

Grove, Inc. has completed an IPO in the amount of $11 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd